



OPEN ACCESS

EDITED BY

Scott J. Roberts,
Royal Veterinary College (RVC),
United Kingdom

REVIEWED BY

Luca Melotti,
University of Padua, Italy
Miguel Sanchez-Valverde,
University of Murcia, Spain

*CORRESPONDENCE

Mónica Rubio-Zaragoza
✉ mrubio@uchceu.es

RECEIVED 16 May 2023

ACCEPTED 17 November 2023

PUBLISHED 11 December 2023

CITATION

Peláez-Gorrea P, Damiá-Giménez E,
Rubio-Zaragoza M, Cuervo-Serrato B,
Hernández-Guerra ÁM, Miguel-Pastor L,
Del Romero-Martínez A, Sopena-Juncosa J,
Torres-Torrillas M, Santana A,
Cugat-Bertomeu R, Vilar-Guereño JM and
Carrillo-Poveda JM (2023) The autologous
chondral platelet-rich plasma matrix
implantation. A new therapy in cartilage repair
and regeneration: macroscopic and
biomechanical study in an experimental sheep
model.

Front. Vet. Sci. 10:1223825.

doi: 10.3389/fvets.2023.1223825

COPYRIGHT

© 2023 Peláez-Gorrea, Damiá-Giménez,
Rubio-Zaragoza, Cuervo-Serrato,
Hernández-Guerra, Miguel-Pastor,
Del Romero-Martínez, Sopena-Juncosa,
Torres-Torrillas, Santana, Cugat-Bertomeu,
Vilar-Guereño and Carrillo-Poveda. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted which
does not comply with these terms.

The autologous chondral platelet-rich plasma matrix implantation. A new therapy in cartilage repair and regeneration: macroscopic and biomechanical study in an experimental sheep model

Pau Peláez-Gorrea^{1,2}, Elena Damiá-Giménez^{1,2},
Mónica Rubio-Zaragoza^{1,2*}, Belén Cuervo-Serrato^{1,2},
Ángel María Hernández-Guerra^{1,2}, Laura Miguel-Pastor^{1,2},
Ayla Del Romero-Martínez^{1,2}, Joaquín Sopena-Juncosa^{1,2},
Marta Torres-Torrillas^{1,2}, Angelo Santana³,
Ramón Cugat-Bertomeu², José Manuel Vilar-Guereño^{2,4} and
Jose Maria Carrillo-Poveda^{1,2}

¹Bioregenerative Medicine and Applied Surgery Research Group, Department of Animal Medicine and Surgery, CEU-Cardenal Herrera University, CEU Universities, Valencia, Spain, ²García Cugat Foundation CEU-UCH Chair of Medicine and Regenerative Surgery, CEU-Cardenal Herrera University, CEU Universities, Valencia, Spain, ³Departament of Mathematics, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain, ⁴Department of Animal Pathology, Instituto Universitario de Investigaciones Biomédicas y Sanitarias, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain

Introduction: Articular cartilage injuries are a severe problem, and the treatments for these injuries are complex. The present study investigates a treatment for full-thickness cartilage defects called Autologous Chondral Platelet Rich Plasma Matrix Implantation (PACI) in a sheep model.

Methods: Chondral defects 8 mm in diameter were surgically induced in the medial femoral condyles of both stifles in eight healthy sheep. Right stifles were treated with PACI and an intraarticular injection with a plasma rich in growth factors (PRGF) solution [treatment group (TRT)], while an intraarticular injection of Ringer's lactate solution was administered in left stifles [Control group (CT)]. The limbs' function was objectively assessed with a force platform to obtain the symmetry index, comparing both groups. After 9 and 18 months, the lesions were macroscopically evaluated using the International Cartilage Repair Society and Goebel scales.

Results: Regarding the symmetry index, the TRT group obtained results similar to those of healthy limbs at 9 and 18 months after treatment. Regarding the macroscopic assessment, the values obtained by the TRT group were very close to those of normal cartilage and superior to those obtained by the CT group at 9 months.

Conclusion: This new bioregenerative treatment modality can regenerate hyaline articular cartilage. High functional outcomes have been reported, together with

a good quality repair tissue in sheep. Therefore, PACI treatment might be a good therapeutic option for full-thickness chondral lesions.

KEYWORDS

cartilage regeneration, regenerative medicine, plasma rich in growth factors, autologous platelet rich plasma matrix implantation, force platform, symmetry index

Introduction

Chondral lesions are a frequent source of knee discomfort and dysfunction. Moreover, articular cartilage lesions can lead to a premature onset of Osteoarthritis (OA), having a vastly negative impact on patient's functionality and quality of life (1). The reparative and regenerative capacity of the cartilage is limited because of the absence of blood vessels in the tissue and the inability of chondrocytes to react to tissue damage (2). During the articular cartilage repair process, the newly formed tissue has a fibrous nature; thus, the biomechanical properties of native hyaline cartilage are lost, leading to articular degeneration (3). Several strategies to treat articular cartilage injuries have been proposed, including some palliative techniques like chondroplasty and debridement, reparative strategies such as microfractures, or restorative treatments such as mosaicplasty (osteochondral autograft transfer), osteochondral allograft transplantation, scaffold-based repair (in combination or not with cell therapy), autologous chondrocyte implantation (ACI), or matrix-induced ACI (4, 5). The main limitations of these techniques include fibrocartilage formation without long-lasting improvement, the high cost of the treatments, the need for two surgical procedures, longer recovery times, or variable results in active patients (2, 5). For these reasons, further research is needed to find therapies that improve the actual treatments of cartilage injuries (1).

The use of platelet-rich plasma (PRP) and its derivatives have been shown to enhance regeneration in multiple tissues. Many studies show that growth factors (GFs) within the PRP can lead to an increase in the biosynthesis of the cartilage matrix proteins, stimulate chondrogenic regeneration, and improve chondrocyte proliferation and metabolism (2). Moreover, PRP also contains several proteins (fibrinogen, fibronectin, and vitronectin) that play a key role in tissue repair and regeneration. They enable cell and other molecules adhesion, allow cell conduction, and behave as a support "matrix" for tissue repair (6). It has been demonstrated that when an intraarticular (IA) injection of PRP is inserted into the joint, a three-dimensional network of fibrin containing binding sites is created to enhance cellular adhesion, creating a microenvironment that stimulates the cartilage repair process (7). Another bioproduct is Platelet-Poor Plasma (PPP), which has a lower concentration of platelets than PRP. However, it was proven that PPP accelerates cell migration and facilitates healing-associated cell functions (8). There are different types of PRP depending on the preparation protocol and its content. Plasma Rich in Growth Factors (PRGF) is a type of PRP elaborated by a single centrifugation process that is characterized for being 100% autologous and biocompatible. Additionally, it has a moderate platelet concentration, and it is free of leukocytes and erythrocytes (9, 10). It has an autologous origin; thus, it is considered a safe product with a low incidence of reported adverse effects, which makes it a suitable

treatment for patients with a chondral lesion, especially when other therapeutic options are not recommended (11, 12).

Recently, a novel autologous-made matrix called Autologous Chondral PRP Matrix Implantation (PACI) has been used for the treatment of chondral lesion instead of other techniques (4, 5, 13). PACI consists of hyaline cartilage chips associated with a clot of PRP and PPP in combination with IA PRGF in liquid stage. This has already been assessed for the treatment of full-thickness cartilage and osteochondral knee defects in humans (14, 15) and sheep (2, 16, 17). The novel technique harvests cartilage tissue from the chondral defect and combines it with PRP scaffolds. PRP scaffold works as a bioactive component that interacts with embedded cartilage fragments, inducing chondrocytes migration, proliferation, and differentiation to ease cartilage repair. This therapy provided satisfactory functional results and pain relief, with excellent quantity and quality of the repaired tissue (14, 15). Next, the PRP derivative is used as an adjuvant, instead of a main treatment, in these cases. Along the same line, Dominguez et al. performed a preliminary study in sheep to evaluate the efficacy of PACI in stifle chondral lesions, evaluating the histology and the immunohistochemistry of the repaired tissue to discern the type of collagen (type I or II) and the proportional amount that can be found within the implant (2). This aspect is crucial because type II collagen is the main component of healthy cartilage (90–95%) (18), while the presence of type I collagen in articular cartilage indicates the existence of fibrotic connective tissue (19). Similarly, Alcaide-Ruggiero et al. evaluated the macroscopic appearance, histological structure, and chondrocyte repair in cartilage defects in sheep, and the PACI+PRP groups showed significantly better results in the percentage of defect repair and chondrocytes in the newly formed cartilage tissue at 18 months compared to 9 months (17). Recently, it has been published that the PACI+PRP treatment improves the repair cartilage process in chondral defects with mature hyaline cartilage. It also enhances the structural and mechanical qualities of the repair tissue, achieving a more consistent cartilage that is less susceptible to degradation and to producing hypertrophic formations over time (16). The results of the studies showed that PACI is an optimal technique to repair hyaline cartilage, with an adequate presence of type II collagen and minimal presence of type I collagen (2). Moreover, studies in humans have demonstrated that PACI is a reliable and competent surgical procedure with promising results (15).

Lameness is an obvious manifestation of musculoskeletal disorders (20). Force platform gait analysis is considered the "gold standard" for the objective evaluation of limb function or to evaluate changes related to musculoskeletal limb diseases (21). Gait and movement asymmetries are significant variables for measuring locomotor biomechanics in patients; furthermore, these variables play a key role in the prediction of future injuries or in assessing the success of clinical interventions. The Symmetry Index (SI) is the

measure most often used, where the denominator is taken to be the average of the absolute values for both limbs. SI is the ratio of the gait cycle between the limbs to compare the dominance pattern between study groups (22). To calculate the SI, it is necessary to obtain the ground reaction force data, including the peak vertical force (PVF), and the vertical impulse (VI) (23). Furthermore, the SI measures the degree of symmetry between different limbs and can be used to determine if a patient is clinically sound or lame (24). If the SI is greater than 3%, then it means the animal is lame, while a SI lower than 3% indicates the animal supports the same force on both limbs and is sound (25).

To macroscopically assess the repair of the chondral lesion, the ICRS and Goebel scales are used. The ICRS scale assesses the degree of defect repair, the integration of the border zone, and the general macroscopic appearance of the defect. The ICRS scale defect is scored between 0 (the worst possible result) to 12 (the best possible result) (26). On the other hand, the Goebel scale score uses five major parameters: “the color of the repair tissue,” “the presence of blood vessels in the repair tissue,” “the surface of the repair tissue,” “the filling of the defect,” and “the degeneration of adjacent articular cartilage.” For the Goebel scale, the defect is scored between 0 (excellent repaired tissue) to 20 (no repaired tissue and damaged adjacent area).

The purpose of this study is to evaluate the functional therapeutic potential of PACI for the treatment of stifle full-thickness cartilage defects using a force platform and a macroscopical evaluation in a sheep model. It was hypothesized that this technique would repair articular cartilage, and clinical, biomechanical, and macroscopical improvements would be obtained.

Materials and methods

Animals

The present study was approved by the Bioethical Committee for Animal Experimentation of the CEU-Cardenal Herrera University (2019/VSC/PEA/0162 type 2), and it has strictly complied with the experimental animal legislation adhered to by the Ministry of Agriculture, Fisheries and Food. In the study group, eight skeletally mature Merino sheep with a mean weight of 52 kg were included. An additional four sheep were used as a negative control group. The animals were exhaustively evaluated by a veterinarian to ensure an optimal healthy status and to rule out any orthopedic problems.

Study groups

A full-thickness chondral defect 8 mm in diameter was created in the medial femoral condyles of both stifles in all animals. The right stifles were treated with PACI combined with an IA injection of PRGF (TRT stifles), and the left stifles were treated with a single IA injection of Ringer Lactate solution (RLS; CT stifles).

Presurgical procedure

Before surgery, the animals fasted for 24 h to prevent possible complications caused by regurgitation and tympany during the

procedure and recovery. All sheep were premedicated with 4 mcg/kg IV Dexmedetomidine (Dexdomitor; Orion Pharma, Spain) and 0.2 mg/kg IV Morphine (Morphine 2%; B. Braun). Subsequently, animals were preoxygenated by mask at 5 L/min for a period of 5 min, followed by induction with 1 mg/kg IV Propofol (Propofol Lipide 1%; B. Braun) per minute until endotracheal intubation was performed. Moreover, esophageal catheterization was necessary to avoid ruminal tympany during anesthesia. Anesthetic maintenance was mask-induced and Sevoflurane (Sevoflo; Zoetis Belgium SA) was vaporized in 100% O₂ (IsoTec 5; Datex-Ohmeda, United Kingdom) through a circular air system (S/5 Avance; Datex-Ohmeda anesthesia equipment, Finland).

Patient monitoring was achieved using a multiparametric vital signs monitor (S/5 Datex-Ohmeda) that consisted of an electrocardiogram, a pulsometer, a capnography, body temperature, and invasive blood pressure.

After aseptic surgical field preparation, surgery was performed in both stifles

Surgical procedure

A 3–4 cm mini-arthrotomy was performed after medial parapatellar approach. Thereafter, the weight bearing area of the medial femoral condyle was identified and the defect was created using an 8-mm diameter punch. Subsequently, this cartilage area was removed using a number 15 scalpel blade (Figure 1). The healthy hyaline cartilage samples were then cut into small fragments (1–2 mm³) and mixed with the activated PRP and PPP to obtain a clot. This clot worked as a scaffold for the cartilage chips (Figure 2). Once the PACI+PRP matrix was solidified, it was placed, filling the cartilage defect (Figure 3).

The right knees of all individuals were treated with PACI. Just 5 to 10 min after PACI application on the defect, the joint was subjected to passive flexion and extension movements to ensure biological adhesion of the therapy. Subsequently, conventional closure was performed with a simple continuous suture pattern of the joint capsule with 0 polygluconate (Monosyn[®], B Braun).

In the left knee, the lesion was created following the same procedure, but no treatment was applied.

Then, all animals received a single 2 mL IA injection of PRGF on the right joints, while the left joints were IA injected with 2 mL of RLS. Antibiotherapy (Amoxicillin 15 mg/kg IM, Amoxicilina 15%, Virbac, Spain) and analgesia (Buprenorphine 0.02 mg/kg IM, Buprecare 0.3 mg/mL, Ecuphar, Spain) were given during a 5-day period.

After anesthesia recovery, animals were housed in species-appropriate facilities without movement restriction. No casts, bandages, or splints were used.

Autologous chondral platelet-rich plasma matrix implantation and plasma rich in growth factors: preparation and use

Before the surgical procedure, a total of 36 mL of blood was collected from the right jugular vein of each animal with a 16 g sterile




FIGURE 1

Surgical procedure. 8 mm punch placement in the load area in medial femoral condyle (A); delimitation of the defect area by using a punch and a surgical hammer (B); delimitated cartilage area for posterior removal (C); cartilage removal by using a number 15 blade scalpel (D); articular cartilage removal (E); created defect (F).




FIGURE 2

PACI creation. Cartilage fragment from the loading area of the medial femoral condyle (A); fragmentation of the articular cartilage into small pieces (1-2 mm²) (B); PACI formation into a punt (C); minced cartilage together with the activated PRP (D); PRP gelification (E); obtained PACI (F).

needle for PRGF preparation and for blood testing to ensure the animal's healthy status.

PRGF was prepared following PRGF Endoret® methodology (Biotechnology Institute, Vitoria, Spain) and considering the data of the preliminary study (2). 25 mL of blood was collected from the jugular vein of each animal just prior surgery into 5 mL sodium citrate solution (3.8%) extraction tubes. The different blood phases were separated by centrifuging the tubes for 8 min at 630g. The fraction located just above the buffy coat (white fraction) corresponded to PRGF; moreover, another fraction located just below the PRGF

corresponded to PPP, which has demonstrated clinical efficacy (1, 2). Prior to infiltration and clot preparation, the platelets were activated using calcium chloride 10% (CaCl₂ 10%) at a rate of 50 μL per milliliter of plasma, and the tubes were kept at room temperature (27).

The activated PPP and PRP fractions (50/50 ratio) were collected and used to prepare the clot together with the cartilage chips obtained during the surgical procedure with the 8 mm punch, creating the PACI regenerative therapy. A mean time of less than 1 h elapsed between blood collection to PRP and PPP application. A single treatment with growth factors was intraoperatively applied (2).




FIGURE 3
Placement of PACI in the chondral lesion of the medial condyle of the right stifle.

Force platform

Animals were evaluated 1, 3, 9, and 18 months after surgery using a force platform. Once the PVF in the TRT and CT stifles was obtained, reference values were also obtained in healthy stifles (HS). Then, the SI for each animal was obtained. For data recording, a force platform was placed at the center of a 6 m runway covered by a rubber mat, and the sheep were forced to walk over it. Walking speed was measured by a motion sensor (PS-2103a, Pasco, CA, United States). To ensure the homogeneity of the samples, only the samples recorded within a narrow variation of velocity (1.6 ± 0.5 m/s) and acceleration (≤ 0.5 m/s²) were considered valid. In addition, the limbs must have contacted the center of the force platform during recording to be considered valid. Three valid trials per sheep were obtained. The sampling frequency was set to 250 Hz. The software DataStudio® (Pasco, CA, United States) was used for the acquisition, numerical conversion, and storage of data.

The TRT and CT stifles were compared by means of the use of the SI. The following formula to obtain the SI was used:

$$SI = 200 (V_{TRT} - V_{CT}) / (V_{TRT} + V_{CT})$$

where V_{TRT} is the PVF value in the limb PACI and V_{CT} is the PVF value of the variable measured in the limb RLS.

Macroscopic evaluation

Animals were euthanized at 9 and 18 months (four animals at each study time) post-surgery to evaluate the repaired tissue. Digital high-resolution photographs of the articular surface of the medial femoral condyle were taken. The macroscopic repair process was assessed by four blinded observers. Two different scales were used: the validated ICRS (26) scale and a scoring system developed and validated in a sheep model in 2012 by Goebel et al. (28). The ICRS and Goebel scales

were assessed in four sheep at month 9 and the remaining four at month 18.

Statistical study

The sample size was calculated by a power analysis consistent with results published in prior research conducted by Milano et al. (29). An alpha level of 0.05 and a power of 80% were established. The following equation was used:

$$n = \frac{2(Z_{\alpha} + Z_{\beta})^2 * S^2}{d^2}$$

For the statistical analysis of data, a linear mixed effects model has been used (30, 31). For each response variable (TRT, CT, and SI), the month has been considered as the fixed effects factor, while the sheep is a random effects factor. The model is as follows:

$$y_{ij} = \mu_i + b_j + \varepsilon_{ij}, \quad i = 0, 1, 3, 9, 18, \quad j = 1, \dots, 8$$

$$b_j \approx N(0, \sigma_b) \quad \varepsilon_{ij} \approx N(0, \sigma)$$

where:

y_{ij} : is the measure in the i -th month ($i = 0, 1, 3, 9, 18$) on the sheep j ($j = 1 \dots 8$).

μ_i is the (fixed) effect of the month i . This parameter represents the mean value of the variable that month.

b_j is the (random) effect of sheep j . Values of b_j are supposed to be normally distributed with a mean of 0 and a standard deviation of σ_b . So, σ_b is the variability in the response due to the sheep.

ε_{ij} is the residual in the measure ij . This variable is assumed to be also normally distributed with the mean 0 and the standard deviation σ .

Parameters in this model are estimated by using the package nlme in the R statistical software (The R Project for Statistical Computing). The Tukey type post-hoc test was applied for locating significant differences when the overall test is significant. The Shapiro–Wilk test was used to assess the normality of the residuals, and the Levene test was applied to evaluate homoscedasticity.

Regarding the macroscopical assessment, the data were analyzed using linear mixed effects models. The “limb” and “month” were considered fixed effects, and the “sheep” and “observer” were considered random effects. The response variable was transformed using a Box-Cox transformation when necessary to achieve the normality of the residuals. The normality of the residuals was tested by the Shapiro–Wilk test. Results are shown as adjusted means (\pm SD) for each month, stifle, and scale, and as differences between stifles or between months, with corresponding 95% confidence intervals (CI). The significance of the differences has been assessed by type III analysis of variance, using the Satterthwaite method to adjust the degrees of freedom. Differences with p -values of less than 0.05 were considered significant.

To evaluate these results, we have taken adjusted mean values per limb, and they are shown for an “average” observer and an “average”

TABLE 1 This table shows mean and standard deviation of each variable (TRT group, CT group, difference, and SI), initially and after 1, 3, 9, and 18 months.

Month	TRT	CT	Difference	SI
0	273.73 ± 1.98	273.68 ± 2.00	0.05 ± 2.57	0.02 ± 0.94
1	294.18 ± 1.54	246.90 ± 1.12	47.28 ± 2.04	17.47 ± 0.74
3	292.43 ± 1.46	253.74 ± 1.72	38.69 ± 2.09	14.17 ± 0.78
9	276.11 ± 2.65	252.10 ± 2.90	24.01 ± 3.22	9.09 ± 1.23
18	275.50 ± 1.56	250.77 ± 2.02	24.73 ± 3.41	9.40 ± 1.31

TABLE 2 This table shows the range (minimum and maximum) of each variable each month.

Month	TRT	CT	Difference	SI
0	[270.7; 276.4]	[271.6; 277.9]	[-4.8; 3.4]	[-1.7; 1.2]
1	[291.6; 296.2]	[244.4; 248.1]	[43.5; 49.4]	[16.1; 18.2]
3	[290.7; 295.3]	[250.9; 256.7]	[34.0; 41.0]	[12.4; 14.9]
9	[272.6; 279.7]	[248.9; 256.3]	[20.5; 30.8]	[7.8; 11.6]
18	[273.2; 276.6]	[248.7; 253.2]	[20.0; 27.9]	[7.6; 10.6]

TABLE 3 Analysis of PACI (TRT group).

Comparison	Difference	CI95.	<i>p</i>
Month 1 – Month 0	20.45	[17.92, 22.98]	<0.0001
Month 3 – Month 0	18.7	[16.17, 21.23]	<0.0001
Month 9 – Month 0	2.38125	[-0.15, 4.91]	0.0759
Month 18 – Month 0	1.775	[-1.33, 4.88]	0.4995

sheep. The concept of adjusted mean has to do with the way the model has been estimated to analyze the data. The limb has been considered a fixed effect, one limb has treatment and the other does not, and the objective of the study is to compare the PACI treatment with the RLS control. On the other hand, the observer and the sheep are considered random effects. The model estimates the variability between scores due to having different observers and different sheep, and it then estimates the score that would have been given by an “average observer” to an “average sheep.”

Results

Force platform

Tables 1, 2 show the differences between the mean value of TRT limbs and CT limbs at each study time and its mean value at the beginning of the study ($t=0$) before the creation of the defect. For each difference that differs from 0, there is a 95% CI and the value of p for testing.

With regards to SI, significant differences ($p < 0.0001$) between the healthy limbs and the TRT limbs have been reported at 1- and 3-month follow up. However, no significant differences have been noticed between these two groups at 9- and 18-month follow up. Note that the SI in the TRT group increases significantly in months 1 and 3, but in months 9 and 18, its value remains stable (Table 3; Figure 4).

Moreover, significant differences ($p < 0.0001$) between the CT group and HS have been shown at every study time, which means that the SI results obtained in the CT group showed statistically significant differences in all the analysis times (1, 3, 9, and 18 months; Table 4; Figure 5).

The model complies with the hypotheses of normality (Shapiro test $p = 0.2362$) and homoscedasticity (Levene test $p = 0.1596$; Tables 1, 2, 5; Figure 6).

Macroscopic evaluation

The result of the analysis of these two scales shows better macroscopical articular cartilage regeneration in the TRT group compared to the CT group at 9 months. There were statistically significant differences when comparing the difference in the values of each macroscopic scale between TRT and CT at 9 months (Table 6).

The mean scores for both macroscopical scales on each knee at 9- and 18-month follow up are compared in Table 7. There are no significant differences in any group between the scores obtained at 9- and 18-month follow up (Figure 7).

Discussion

In recent years, the application of previously minced small cartilage chips have achieved good results (32, 33). Some human and animal studies prove that there is better quality of repaired cartilage when minced cartilage treatments are used (34–36). This technique enhances the relocation of chondrocytes into the biomaterial and the subsequent cartilaginous extracellular matrix (ECM) deposition by these cells (37). Moreover, the IA application of PRP enhances cell migration and promotes chondrocyte viability, proliferation, and differentiation, which is essential during the chondrogenesis process (38, 39).

The present study aims to evaluate whether an aggregate of hyaline cartilage in a suspension of PRGF gel with the infiltration of PRGF IA in the stifle of a sheep with a chondral injury has satisfactory results. Currently, this treatment, called PACI, has been used in chondral injuries in humans, obtaining an optimal evolution of the patient evidenced by the improvement of clinical signs and imaging tests (15). In this sense, our working hypothesis is that the application of an autologous-made matrix involving hyaline cartilage “chips” mixed with a PRGF-based clot, together with the IA infiltration of PRGF in sheep with a chondral stifle injury, will achieve an optimal clinical evolution. The effectiveness was assessed by functionality tests and objective force platform gait analysis. In addition, we believe that this new biological therapy produces the repair with hyaline cartilage with similar characteristics to the healthy one, which will be evidenced with macroscopic study.

In our study, the healthy hyaline cartilage used in the TRT group was cut into 1–2 mm³ fragments. It is important to consider the degree of fragmentation of the cartilage chips because it influences the amount of ECM production (40). Similar to our study, Alcaide-Ruggiero et al. fragmented the cartilage particles into cubes of 1–2 mm³, obtaining promising results in cartilage repair (17). Moreover, Anitua et al. have recently published that the mean size of the cartilage fragments should be 1.7 mm² (41).




FIGURE 4 Analysis of PACI (TRT group).

TABLE 4 Analysis of RLS (CT group).

Comparison	Difference	CI95.	p
Month 1 – Month 0	–26.775	[–29.45, –24.10]	<0.0001
Month 3 – Month 0	–19.938	[–22.61, –17.26]	<0.0001
Month 9 – Month 0	–21.575	[–24.25, –18.90]	<0.0001
Month 18 – Month 0	–22.9	[–26.18, –19.62]	<0.0001

TABLE 5 This table shows the global range of each variable.

TRT	CT	Difference	SI
[270.7; 296.2]	[244.4; 277.9]	[–4.8; 49.4]	[–1.7; 18.2]

In reference to the macroscopic study at 9 months, the TRT group showed significantly better results than the CT group (Table 6). In accordance with our results, Alcaide-Ruggiero et al. have recently published a study in which 16 sheep were included. The animals were divided into two groups (n=8). In the first group, left stifles were treated with RLS, while right stifles were treated with PACI+PRP. In the second group, left knees were treated with hyaluronic acid (HA), and PACI+PRP was used for the right knees. The sheep were euthanized at 9 and 18 months after surgery, and the macroscopic evaluation showed that PACI+PRP patients had better macroscopic appearance than the RLS and HA animals, especially at 18-month follow up. This group has recently published the use of PACI+PRP treatment in knee chondral defects, showing an improvement in the repair of the cartilage process, with the presence of mature hyaline cartilage that shows better functional characteristics (16, 17). In the same line, Dominguez et al. conducted a study with sheep to analyze the repair tissue macroscopically, histologically, and immunohistochemically after the application of the PACI treatment. The results of this study showed that this technique was able to repair hyaline articular cartilage with an

adequate presence of type II collagen and little presence of type I collagen. The authors observed that this novel treatment promoted chondrogenesis and regenerated hyaline cartilage at 6-month follow up with closely normal macroscopic ICRS assessment (2). Similar results were obtained by Milano et al. in which the ICRS macroscopic scale was used to assess full-thickness chondral lesions of the medial femoral condyle in 15 sheep. All sheep were treated with a microfracture surgical technique, but better ICRS scores were obtained in animals additionally treated with a fibrin glue gel implant combined with PRP than in the ones only treated with microfractures or microfractures together with PRP injections (13).

Limb function was also assessed in our study. Our results showed that at 1-month follow up, there were significant differences between the TRT group and the HS group, because the animals supported more weight on the treated limb than on sound limbs. This could be explained because both limbs were subjected to a surgery; therefore, more weight was loaded onto less painful limbs to compensate for the hurt limb. In the same way, at 3-month follow up, significant differences between the TRT group and the HS were reported. However, at 9-and 18-month follow up, the TRT group and the HS group were reported, meaning the TRT limb supported the same weight as the HS limb. On the contrary, the SI results obtained in the CT group showed significant differences with the HS group during all the study times (1, 3, 9, and 18 months), meaning the sheep never achieved the same limb function after surgery. These results cannot be compared with previously published results because, to our knowledge, no force platform analysis has been conducted in sheep. However, some research in dogs have extensively studied the compensatory mechanisms between sound and affected limbs (13, 42–45).

In humans, the first publication of two patients with full-thickness chondral lesions treated with PACI were professional soccer players (14). The study concluded that pain relief was satisfactory, and the players returned to the same level of functionality they had prior to




FIGURE 5
Analysis of RLS (CT group).




FIGURE 6
Shows mean and standard deviation of each variable (TRT group, CT group, difference, and SI), initially and after 1, 3, 9, and 18 months.

the injury. These results are similar to the ones obtained in our study, where stifles treated with PACI also returned to full functionality, objectively generating force loads equal to those of a healthy limb. Also, in the same study, the authors reported that in a second-look arthroscopy, they observed a similar appearance and consistency on

palpation of the new cartilage to the immediate healthy articular cartilage. However, it was not possible to analyze the repair tissue histologically and immunohistochemically (14). The same research group confirmed good clinical and functional results in a clinical study performed on 15 patients with full-thickness knee cartilage

TABLE 6 Results obtained for the different parameters in both ICRS and Goebel scales for stifles treated with PACI and RLS (±SD).

Scale	Macroscopic parameters	TRT		CT	
		9 months	18 months	9 months	18 months
ICRS	Repair	2.94 ± 1.00	3.75 ± 0.45	2.31 ± 0.95	3.19 ± 0.75
	Integration	2.38 ± 0.72	3.31 ± 0.60	2.12 ± 0.72	2.44 ± 0.73
	Appearance	2.12 ± 0.72	3.19 ± 0.66	1.75 ± 0.68	2.31 ± 0.79
	General	7.56 ± 2.28	10.12 ± 1.41	6.19 ± 2.10	7.94 ± 1.84
GOEBEL	Color	1.31 ± 0.60	0.31 ± 0.48	1.44 ± 0.81	1.19 ± 0.40
	Vessel	0.06 ± 0.25	0.00 ± 0.00	0.56 ± 0.73	0.31 ± 0.48
	Surface	1.44 ± 1.03	0.69 ± 0.79	2.00 ± 0.73	1.50 ± 0.89
	Filling	0.94 ± 0.85	0.50 ± 0.52	1.31 ± 0.70	1.00 ± 0.63
	Degeneration of adjacent articular cartilage	1.25 ± 0.45	0.44 ± 0.51	1.75 ± 0.86	1.50 ± 0.73
	General	5.00 ± 2.83	2.00 ± 1.71	7.00 ± 3.33	5.50 ± 1.86

TABLE 7 The following table shows the mean difference (±SD) between the legs (treatments) at 9 and 18 months in general parameters of scales.

Month	Scale	CT	TRT	Diff CT – TRT (95%CI)	P	Shapiro.P
9	ICRS	6.19 (1.13)	7.56 (1.25)	-1.38 (-2.64, -0.11)	0.0401	0.2089
	GOEBEL	7.00 (1.85)	5.00 (1.56)	2.00 (1.17, 3.46)	0.0393	0.1314
18	ICRS	7.94 (0.84)	10.12 (0.57)	-2.19 (-4.97, 0.60)	0.0872	0.9028
	GOEBEL	5.50 (0.96)	2.00 (0.79)	3.50 (-0.19, 7.19)	0.0590	0.4295
Treatment	Scale	Month 9	Month 18	Diff 9–18 months (95%CI)	P	Shapiro.P
TRT	ICRS	7.56 (1.25)	10.12 (0.57)	-2.56 (-7.55, 2.42)	0.1643	0.0615
	GOEBEL	5.00 (1.56)	2.00 (0.79)	3.00 (-0.42, 6.42)	0.0508	0.1208
CT	ICRS	6.19 (1.13)	7.94 (0.84)	-1.75 (-5.64, 2.14)	0.2845	0.7250
	GOEBEL	7.00 (1.85)	5.50 (0.96)	1.50 (-3.62, 6.62)	0.4757	0.0561
Difference	ICRS	-1.38 (1.07)	-2.19 (1.07)	0.81 (-2.81, 4.44)	0.6066	0.6951
	GOEBEL	2.00 (1.02)	3.50 (1.02)	-1.50 (-4.20, 1.20)	0.2497	0.2708

defects or osteochondritis dissecans based on MRI findings (quality and quantity of cartilage repair) in 2020. Actually, this research group has used PACI in more than 150 patients with chondral defects in different joints for over 5 years. They have reported good clinical, functional, and MRI-based results (15).

The good results reported in our study and in research previously published regarding histology and functional outcomes after PACI treatment could be explained by the results obtained by Anitua et al. in an *in vitro* research study recently published. The authors concluded that cartilage fragments embedded into the three-dimensional PRGF scaffold contained viable chondrocytes that were able to migrate into the fibrin network and proliferate and synthesize the extracellular matrix after the second week of *in vitro* culture (41).

One of the purposes of our study is to demonstrate that PACI is a therapy that can replace other repair techniques for articular cartilage injuries, for instance ACI. The ACI technique requires *in vitro* expansion of the patient’s chondrocytes, which requires about 4 weeks, so cell dedifferentiation may occur. In addition, this technique can present drawbacks, such as a high cost for the production of cells, different surgical interventions, and a long time to return to functional activity (29). These types of complications raise the importance of creating new regenerative and reparative therapies for chondral defects, which manage to obtain normal

hyaline cartilage. In recent years, other therapies have been investigated, such as infiltrations with PRP and MSCs. MSCs synthesize trophic factors with regenerative functions, and they are able to differentiate into cartilaginous and osseous cells, favoring articular cartilage regeneration (46). The IA infiltration of this regenerative therapy facilitates the expression of molecules with chondrogenic and anti-inflammatory activity, and it has been demonstrated that they generate an environment that favors the recruitment and activation of stem cells on site, enhancing the repair of articular cartilage (47). Regarding the treatment of articular cartilage injuries with PRP (which we combined in the present study with cartilage chips), different studies demonstrated that PRP regulates cartilage repair by stimulating the secretion of type II collagen, aggrecans, or proteoglycans; stimulating the chondrogenic differentiation of MSCs; and proliferating synoviocytes. Additionally, PRP reduces the catabolic effects of cytokines, such as IL-1, and of proteolytic enzymes, like matrix metalloproteinases (27, 46, 48). We must consider that it is especially valuable to provide alternative, minimally invasive therapeutic modalities that might significantly halt the disease progression in patients with chondral lesions. The main finding of this study is that this new treatment modality is able to regenerate hyaline articular cartilage. The present research provided superior functional outcomes with a better macroscopical




FIGURE 7
Macroscopic digital photographs of chondral defects: Group CT (RLS) 9months and 18months; Group TRT (PACI) 9months and 18months.

appearance of the cartilage repair tissue in sheep. Bioregenerative therapies have proven to be a better option over other treatments due to their therapeutic potential. In recent years, these therapies have been proposed as a promising alternative or a complementary therapy to conventional treatments, with the objective of improving tissue regeneration. The main limitation of this study is that our sheep underwent the surgical procedure in both right and left stifle. Ideally, only one stifle per sheep should be operated on in order to compare the healthy stifle with the damaged stifle within the same animal. Moreover, sheep did not follow any kind of movement restriction, thus the sheep could have suffered a matrix detachment during the first days after PACI implantation.

Conclusion

Our results showed that PACI-treated limbs obtained values equivalent to those obtained by healthy limbs at 9-and 18-months

follow up. Furthermore, the macroscopical analysis of the postmortem lesions showed better scores in the TRT group than in the CT group at 9-month follow up.

It can be concluded that PACI treatment is a good therapeutic option for full-thickness chondral lesions, as excellent functional recovery has been observed in a sheep model. In addition, the technique is safe because it uses autologous tissue with no probability of refusal by the patient. Moreover, the technique is easy to reproduce and does not require a high economic investment. Nonetheless, further research is required to compare PACI with other treatments and to assess the efficacy of this therapy at longer follow-up periods.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was approved by CEU CARDENAL HERRERA UNIVERSITY. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

JC-P, JV-G, PP-G, and RC-B contributed to conception and design of the study. PP-G, MR-Z, ED-G, JV-G, JC-P, and JS-J analyzed data and wrote the manuscript. AS performed statistical analysis. PP-G, MR-Z, ED-G, JV-G, JC-P, and JS-J wrote the first draft of the manuscript. PP-G, JC-P, ED-G, BC-S, MR-Z, ÁH-G, JS-G, AR-M, LM-P, and MT-T performed the experiment. All authors contributed to the article and approved the submitted version.

Funding

This project received financial support from the García Cugat Foundation CEU-UCH Chair of Medicine and Regenerative Surgery and Santander Bank S.A. The project was also founded by Santander Foundation with grant number: FUSPBS-PPC03/2017.

References

- Cugat R, Alentorn-Geli E, Navarro J, Cuscó X, Steinbacher G, Seijas R, et al. A novel autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the treatment of full-thickness cartilage or osteochondral defects: preliminary results. *J Orthop Surg (Hong Kong)*. (2020) 28:2309499019887547. doi: 10.1177/2309499019887547
- Domínguez Pérez JM, Fernández-Sarmiento JA, Aguilar García D, Granados Machuca MDM, Morgaz Rodríguez J, Navarrete Calvo R, et al. Cartilage regeneration using a novel autologous growth factors-based matrix for full-thickness defects in sheep. *Knee Surg Sports Traumatol Arthrosc*. (2019) 27:950–61. doi: 10.1007/s00167-018-5107-z
- Peláez P, Damiá E, Torres-Torrillas M, Chicharro D, Cuervo B, Miguel L, et al. Cell and cell free therapies in osteoarthritis. *Biomedicine*. (2021) 9:1726. doi: 10.3390/biomedicines9111726
- Devitt BM, Bell SW, Webster KE, Feller JA, Whitehead TS. Surgical treatments of cartilage defects of the knee: systematic review of randomised controlled trials. *Knee*. (2017) 24:508–17. doi: 10.1016/j.knee.2016.12.002
- Welton KL, Logterman S, Bartley JH, Vidal AF, McCarty EC. Knee cartilage repair and restoration: common problems and solutions. *Clin Sports Med*. (2018) 37:307–30. doi: 10.1016/j.csm.2017.12.008
- Ha CW, Park YB, Jang JW, Kim M, Kim JA, Park YG. Variability of the composition of growth factors and cytokines in platelet-rich plasma from the knee with osteoarthritis. *Art Ther*. (2019) 35:2878–84.e1. doi: 10.1016/j.arthro.2019.04.010
- Anitua E, Sánchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. *Adv Drug Deliv Rev*. (2010) 62:741–52. doi: 10.1016/j.addr.2010.01.001
- Creeper F, Ivanovski S. Effect of autologous and allogenic platelet-rich plasma on human gingival fibroblast function. *Oral Dis*. (2012) 18:494–500. doi: 10.1111/j.1601-0825.2011.01897.x
- Nishiyama K, Okudera T, Watanabe T, Isobe K, Suzuki M, Masuki H, et al. Basic characteristics of plasma rich in growth factors (PRGF): blood cell components and biological effects. *Clin Exp Dent Res*. (2016) 2:96–103. doi: 10.1002/cre2.26
- Wu PI, Diaz R, Borg-Stein J. Platelet-rich plasma. *Phys Med Rehabil Clin N Am*. (2016) 27:825–53. doi: 10.1016/j.pmr.2016.06.002
- Sun Q, Zhang L, Xu T, Ying J, Xia B, Jing H, et al. Combined use of adipose derived stem cells and TGF- β 3 microspheres promotes articular cartilage regeneration in vivo. *Biochem Histochem*. (2018) 93:168–76. doi: 10.1080/10520295.2017.1401663
- Ozeki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K, et al. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees

Acknowledgments

The authors would like to thank the García Cugat Foundation for its founding support. Additionally, we would like to thank the Veterinary Teaching Hospital and Research and Teaching Farm of the Cardenal Herrera University, specially to Paula Martínez and Amparo Gálvez for their support and taking care of the animals. Tanks too to Ignacio Muñoz Criado, IMSKE Hospital medical head for his research collaboration.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

and inhibit osteoarthritis progression in rats. *Osteoarthr Cartil*. (2016) 24:1061–70. doi: 10.1016/j.joca.2015.12.018

13. Milano G, Sanna Passino E, Deriu L, Careddu G, Manunta L, Manunta A, et al. The effect of platelet rich plasma combined with microfractures on the treatment of chondral defects: an experimental study in a sheep model. *Osteoarthr Cartil*. (2010) 18:971–80. doi: 10.1016/j.joca.2010.03.013

14. Cugat R, Alentorn-Geli E, Steinbacher G, Álvarez-Díaz P, Cuscó X, Seijas R, et al. Treatment of knee osteochondral lesions using a novel clot of autologous plasma rich in growth factors mixed with healthy hyaline cartilage chips and intra-articular injection of PRGF. *Case Rep Orthop*. (2017) 2017:1–6. doi: 10.1155/2017/8284548

15. Cugat R, Samitier G, Vinagre G, Sava M, Alentorn-Geli E, García-Ballebó M, et al. Particulated autologous chondral-platelet-rich plasma matrix implantation (PACI) for treatment of full-thickness cartilage osteochondral defects. *Arthrosc Tech*. (2021) 10:e539–44. doi: 10.1016/j.eats.2020.10.038

16. Alcaide-Ruggiero L, Molina-Hernández V, Morgaz J, Fernández-Sarmiento JA, Granados MM, Navarrete-Calvo R, et al. Immunohistochemical analysis of knee chondral defect repair after autologous Particulated cartilage and platelet-rich plasma treatment in sheep. *Int J Mol Sci*. (2023) 24:157. doi: 10.3390/ijms242015157

17. Alcaide-Ruggiero L, Molina-Hernández V, Morgaz J, Fernández-Sarmiento JA, Granados MM, Navarrete-Calvo R, et al. Particulate cartilage and platelet-rich plasma treatment for knee chondral defects in sheep. *Knee Surg Sports Traumatol Arthrosc*. (2023) 31:2944–55. doi: 10.1007/s00167-022-07295-7

18. Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review of management. *Br Med Bull*. (2008) 87:77–95. doi: 10.1093/bmb/ldn025

19. Alcaide-Ruggiero L, Molina-Hernández V, Granados MM, Domínguez JM. Main and minor types of collagens in the articular cartilage: the role of collagens in repair tissue evaluation in chondral defects. *Int J Mol Sci*. (2021) 22:24. doi: 10.3390/ijms222413329

20. Deeming LE, Beausoleil NJ, Stafford KJ, Webster JR, Zobel G. Technical note: the development of a reliable 5-point gait scoring system for use in dairy goats. *J Dairy Sci*. (2018) 101:4491–7. doi: 10.3168/jds.2017-13950

21. Liu X, Kui H, Qian Z, Ren L. Hoof pressure distribution pattern of blue sheep during walking on different slopes: a subject-specific analysis. *Front Vet Sci*. (2021) 8:633509. doi: 10.3389/fvets.2021.633509

22. Queen R, Dickerson L, Ranganathan S, Schmitt D. A novel method for measuring asymmetry in kinematic and kinetic variables: the normalized symmetry index. *J Biomech*. (2020) 99:109531. doi: 10.1016/j.jbiomech.2019.109531

23. Volstad NJ, Sandberg G, Robb S, Budsberg SC. The evaluation of limb symmetry indices using ground reaction forces collected with one or two force plates in healthy dogs. *Vet Comp Orthop Traumatol.* (2017) 30:54–8. doi: 10.3415/VCOT-16-04-0054
24. Schnabl-Feichter E, Tichy A, Bockstahler B. Evaluation of a pressure plate for detection of hind limb lameness in cats. *PLoS One.* (2020) 15:e0231904. doi: 10.1371/journal.pone.0231904
25. Hernández-Guerra Á, Carrillo JM, Sopena JJ, Vilar JM, Peláez P, Cuervo B, et al. Platelet-rich plasma for the treatment of degenerative lumbosacral stenosis: a study with retired working dogs. *Animals (Basel).* (2021) 11:965. doi: 10.3390/ani11102965
26. van den Borne MP, Rajmakers NJ, Vanlauwe J, Victor J, de Jong SN, Bellemans J, et al. International cartilage repair society (ICRS) and Oswestry macroscopic cartilage evaluation scores validated for use in autologous chondrocyte implantation (ACI) and microfracture. *Osteoarthr Cartil.* (2007) 15:1397–402. doi: 10.1016/j.joca.2007.05.005
27. Garbin LC, Olver CS. Platelet-rich products and their application to osteoarthritis. *J Equine Vet.* (2020) 86:102820. doi: 10.1016/j.jevs.2019.102820
28. Goebel L, Orth P, Müller A, Zurakowski D, Bücken A, Cucchiari M, et al. Experimental scoring systems for macroscopic articular cartilage repair correlate with the MOCART score assessed by a high-field MRI at 9.4 T – comparative evaluation of five macroscopic scoring systems in a large animal cartilage defect model. *Osteoarthr Cartil.* (2012) 20:1046–55. doi: 10.1016/j.joca.2012.05.010
29. Thompson CL, Plant JC, Wann AK, Bishop CL, Novak P, Mitchison HM, et al. Chondrocyte expansion is associated with loss of primary cilia and disrupted hedgehog signalling. *Eur Cell Mater.* (2017) 34:128–41. doi: 10.22203/eCM.v034a09
30. Pinheiro J. Fitting linear mixed-effects models. *Mixed-effects models in S and S-PLUS.* (2000) 2000:133–97. doi: 10.1007/978-1-4419-0318-1
31. Milliken GAJD. Analysis of mixed models/case studies of a mixed model In: *Analysis of messy data.* GA Milliken and DE Johnson editors. Second ed. Florida: Taylor and Francis Group. (2009)
32. Massen FK, Inauen CR, Harder LP, Runer A, Preiss S, Salzmänn GM. One-step autologous minced cartilage procedure for the treatment of knee joint chondral and osteochondral lesions: a series of 27 patients with 2-year follow-up. *Orthop J Sports Med.* (2019) 7:2325967119853773. doi: 10.1177/2325967119853773
33. Lorenz CJ, Freisleder F, Salzmänn GM, Scheibel M. Minced cartilage procedure for one-stage arthroscopic repair of chondral defects at the glenohumeral joint. *Arthrosc Tech.* (2021) 10:e1677–84. doi: 10.1016/j.eats.2021.03.012
34. Grawe B, Burge A, Nguyen J, Strickland S, Warren R, Rodeo S, et al. Cartilage regeneration in full-thickness patellar chondral defects treated with Particulated juvenile articular allograft cartilage: an MRI analysis. *Cartilage.* (2017) 8:374–83. doi: 10.1177/1947603517710308
35. Christensen BB, Olesen ML, Hede KTC, Bergholt NL, Foldager CB, Lind M. Particulated cartilage for chondral and osteochondral repair: a review. *Cartilage.* (2021) 13:1047S–57S. doi: 10.1177/1947603520904757
36. Zhang C, Zhao X, Ao Y, Cao J, Yang L, Duan X. Proliferation ability of particulated juvenile allograft cartilage. *J Orthop Surg Res.* (2021) 16:56. doi: 10.1186/s13018-020-02199-z
37. Farr J, Cole BJ, Sherman S, Karas V. Particulated articular cartilage: CAIS and DeNovo NT. *J Knee Surg.* (2012) 25:23–9. doi: 10.1055/s-0031-1299652
38. Kreuz PC, Krüger JP, Metzläff S, Freymann U, Endres M, Pruss A, et al. Platelet-rich plasma preparation types show impact on chondrogenic differentiation, migration, and proliferation of human subchondral mesenchymal progenitor cells. *Art Ther.* (2015) 31:1951–61. doi: 10.1016/j.arthro.2015.03.033
39. Chu J, Duan W, Yu Z, Tao T, Xu J, Ma Q, et al. Intra-articular injections of platelet-rich plasma decrease pain and improve functional outcomes than sham saline in patients with knee osteoarthritis. *Knee Surg Sports Traumatol Arthrosc.* (2022) 30:4063–71. doi: 10.1007/s00167-022-06887-7
40. Levinson C, Cavalli E, Sindi DM, Kessel B, Zenobi-Wong M, Preiss S, et al. Chondrocytes from device-minced articular cartilage show potent outgrowth into fibrin and collagen hydrogels. *Orthop J Sports Med.* (2019) 7:2325967119867618. doi: 10.1177/2325967119867618
41. Anitua E, Prado R, Guadilla J, Alkhraisat MH, Laiz P, Padilla S, et al. The dual-responsive interaction of Particulated hyaline cartilage and plasma rich in growth factors (PRGF) in the repair of cartilage defects: an in vitro study. *Int J Mol Sci.* (2023) 24:581. doi: 10.3390/ijms241411581
42. Bockstahler BA, Vobornik A, Müller M, Peham C. Compensatory load redistribution in naturally occurring osteoarthritis of the elbow joint and induced weight-bearing lameness of the forelimbs compared with clinically sound dogs. *Vet J.* (2009) 180:202–12. doi: 10.1016/j.tvjl.2007.12.025
43. Katic N, Bockstahler BA, Mueller M, Peham C. Fourier analysis of vertical ground reaction forces in dogs with unilateral hind limb lameness caused by degenerative disease of the hip joint and in dogs without lameness. *Am J Vet Res.* (2009) 70:118–26. doi: 10.2460/ajvr.70.1.118
44. Jevens DJ, DeCamp CE, Hauptman J, Braden TD, Richter M, Robinson R. Use of force-plate analysis of gait to compare two surgical techniques for treatment of cranial cruciate ligament rupture in dogs. *Am J Vet Res.* (1996) 57:389–93.
45. Rumph PF, Kincaid SA, Visco DM, Baird DK, Kammermann JR, West MS. Redistribution of vertical ground reaction force in dogs with experimentally induced chronic hindlimb lameness. *Vet Surg.* (1995) 24:384–9. doi: 10.1111/j.1532-950X.1995.tb01348.x
46. Venator KP, Frye CW, Gamble LJ, Wakshlag JJ. Assessment of a single intra-articular stifle injection of pure platelet rich plasma on symmetry indices in dogs with unilateral or bilateral stifle osteoarthritis from long-term medically managed cranial cruciate ligament disease. *Vet Med (Auckl).* (2020) 11:31–8. doi: 10.2147/VMR.S238598
47. Lopa S, Colombini A, Moretti M, de Girolamo L. Injective mesenchymal stem cell-based treatments for knee osteoarthritis: from mechanisms of action to current clinical evidences. *Knee Surg Sports Traumatol Arthrosc.* (2019) 27:2003–20. doi: 10.1007/s00167-018-5118-9
48. Cuervo B, Rubio M, Chicharro D, Damiá E, Santana A, Carrillo JM, et al. Objective comparison between platelet rich plasma alone and in combination with physical therapy in dogs with osteoarthritis caused by hip dysplasia. *Animals (Basel).* (2020) 10:175. doi: 10.3390/ani10020175